Please try another search
For the nine months ended 30 September 2019, Synthorx Inc revenues was not reported. Net loss applicable to common stockholders increased 25% to $35.4M. Higher net loss reflects Research and development - Balancing val increase from $9.7M to $29.4M (expense), General and administrative - Balancing v increase from $2.2M to $7M (expense), Stock-based Compensation in SGA increase from $101K to $1.4M (expense).
| Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | ||||
| Operating Income | -13.18 | -13.46 | -11.92 | -8.79 |
| Net Income | -12.22 | -12.37 | -10.85 | -8.5 |
| Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|
| Total Assets | 163.67 | 173.39 | 185.27 | 191.51 |
| Total Liabilities | 11.71 | 10.23 | 11.09 | 7.15 |
| Total Equity | 151.96 | 163.17 | 174.18 | 184.36 |
| Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|
| Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
| Cash From Operating Activities | -38.9 | -24.53 | -9.37 | -16.48 |
| Cash From Investing Activities | -131.32 | -140.64 | -137.3 | -0.92 |
| Cash From Financing Activities | 0.39 | 0.34 | 0.02 | 202.09 |
| Net Change in Cash | -169.83 | -164.82 | -146.64 | 184.69 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
